serious MRSA infections, but treatment failures occur despite MRSA strains being tested susceptible according 23 to standard susceptibility methods. Exposure to physiologically relevant concentrations of LL-37 increased the 24 minimum inhibitory concentration (MIC) of S. aureus towards vancomycin by 75%, and resulted in shortened 25 lag-phase and increased colony formation at sub-inhibitory concentrations of vancomycin. Computer 26 simulations using a mathematical antibiotic treatment model indicated that a small increase in MIC might 27 decrease the efficacy of vancomycin in clearing a S. aureus infection. This prediction was supported in a 28 Galleria mellonella infection model, where exposure of S. aureus to LL-37 abolished the antimicrobial effect of 29 Introduction 33 Bacterial resistance to antibiotics is generally associated with genetic changes, such as point mutations in the 34 core genome or acquisition of resistance genes present on mobile genetic elements 1 or intrinsic resistance to 35 antimicrobials, such as in-permeability of the outer membrane of Gram-negative bacteria or the active efflux of 36 antimicrobials provided by chromosomally encoded efflux pumps 2 . Previously, we showed that exposure to the 37 synthetic antimicrobial peptide (AMP) colistin reduces susceptibility to vancomycin in the clinically important, 38 methicillin resistant Staphylococcus aureus (MRSA) strain USA300 via induction of the GraRS cell wall regulon 3 . 39 S. aureus is a human pathogen that causes a variety of diseases and particularly the MRSA clones are becoming 40 widely distributed both in the hospital environment and in the community 4 . MRSA infections are often treated 41 with the glycopeptide antibiotic vancomycin. The CLSI susceptibility breakpoint for vancomycin is 2 µg/ml 5 . 42
However, in the last decade vancomycin-intermediate S. aureus strains (VISA) have emerged with reduced 43 vancomycin susceptibility (MIC = 4-8 μg/ml) 6 . These strains are characterized by chromosomal mutations that 44 reduce negative cell wall charge 7 , increase cell wall thickness 8 or reduce Triton-X mediated autolysis 9 . Even for 45 non-VISA strains vancomycin treatment failures have been linked to strains displaying MIC in the higher end of 46 the susceptibility range (≥1.5 μg/ml) 5,10-13 . Our previous work revealed that upon colistin exposure, S. aureus 47 cells transiently and reversibly induce cellular changes that result in a phenotypic VISA-like appearance 3 . This 48 reduced vancomycin susceptibility state will remain undetectable by routine clinical testing and thus the MIC of 49 vancomycin upon colistin exposure in vivo may be higher than expected from such testing. 50
Colistin is a cationic AMP used in treatment of Gram-negative infections, however AMPs are also major 51 components of the innate immune system and a critical defence against a large number of pathogens 14 . Human 52
AMPs are small, often cationic peptides with broad-spectrum antimicrobial activity caused by membrane-53 damaging pore-formation 14 . An example is the cathelicidin, LL-37 15 , which is expressed in a variety of immune 54 cells, including polymorphonuclear leukocytes (PMN), the first line of defence against invading bacterial 55 pathogens. In the present study, we demonstrate that the human AMP LL-37 transiently reduces susceptibility 56 to vancomycin. 57
Materials and methods

58
Bacterial strains and growth conditions 59 S. aureus USA300 FPR3757 16 was obtained from the American Type Culture Collection (ATCC). S. aureus strains 60 were routinely grown in Mueller-Hinton (MH) medium (Sigma) at 37°C in Erlenmeyer flasks with aeration. 61
62
Minimum inhibitory concentration 63
To assess vancomycin susceptibility of S. aureus exposed to LL-37 (Sigma), S. aureus FPR3757 was diluted to 10 5 64 CFU/ml in Mueller-Hinton (MH) media and incubated for 1 h (200 rpm, 37 °C). Pre-treatment with either 10 or 65 20 μg/ml LL-37 for 1 h was followed by supplementation of vancomycin (Sigma) and the minimum inhibitory 66 concentration (MIC) was determined in a 96-well microtiter plates (200 rpm, 37 °C, 24 h using technical 67 duplicates and biological triplicates). 68 69 Vancomycin susceptibility testing by plating 70 Exponential phase S. aureus FPR3757 cultures were adjusted to OD 600 = 0.25 in pre-heated MH broth and was 71 then treated with sub-inhibitory concentrations of LL-37 (0, 5, 10, 20 and 40 μg/ml) for 1 h. The cultures were 72 adjusted to OD 600 = 0.1 before spotting 10 μl aliquots of serial four-fold dilutions on freshly prepared MH agar 73 plates containing increasing concentrations of vancomycin (0, 1, 1.25 and 1.5 μg/ml). 74
In one experiment, cultures of S. aureus FPR3757 were grown with 10 μg/ml LL-37 for 60 min and LL-37 was 75 removed from the medium by spinning (5,000g, 5 min, room temperature) and re-suspended in pre-heated MH 76 broth in a subset of the culture, while exposure to LL-37 was maintained in the other subset. After 0, 60 and 90 77 min, the cultures where plated on agar plates containing vancomycin (1.5 μg/ml). 78
The agar plates were inspected for growth following 24 h incubation. 79
Growth experiments 80
Overnight cultures were diluted to approx. 10 5 CFU/ml in fresh MH broth, and incubated for 1 h at 37°C and 81 200 rpm. The culture was then split in appropriate aliquots and treated with LL-37 or left untreated for 1 h at 82 37°C and 200 rpm. The untreated and pre-treated cultures were then split in appropriate aliquots and treated 83 with vancomycin (Sigma) or left untreated. These were then further aliquoted into the wells of a 100-well 84 honeycomb plate and incubated in a Bioscreen C Analyzer (Oy Growth Curves Ab Ltd, Helsinki, Finland) at 37°C 85 and medium continuous shaking. 86 87
Determination of Triton X-100 induced autolysis 88
Strains were grown in MH broth at 37°C, 180 rpm, to mid-exponential phase. The cultures were diluted to an 89 OD 600 of 0.15 in warm MH, grown to an OD 600 of 0.25, and 10 μg/ml LL-37 was added to one subset of cultures 90 while another subset of cultures served as the unexposed control. After 1 h, the cultured cells were washed 91 twice in ice-cold sterile distilled water and resuspended in the same volume of 0.05 M Tris-HCl (pH 7.2) 92 containing 0.05% Triton X-100. Cells were incubated at 30°C, and the OD 600 was measured every 30 min. Data 93 are expressed as the percent loss of OD 600 at the indicated times compared to findings at time zero. Each data 94 point represents the mean and standard deviation from three independent experiments. 95 96 A model of antibiotic treatment 97
Using previous models 17 , the following model was derived to test the effect of a higher MIC on clearance when 98 treated with the same antibiotic concentration. In a continuous flow at rate w a bacterial population (P) is 99 limited by the concentration of a resource (R; µg/ml). An antibiotic of concentration (A; µg/ml) is dosed every 8 100 hours and the concentration declines exponentially at rate d per day, due to flow from the site of infection. The 101 population replicates at maximum rates V MAX and the rates of growth are proportional to the concentration of 102 the resource and antibiotic. For the antibiotic-mediated killing, we assume hill functions so that at an antibiotic 103 concentration of A and resource concentration of R, the net growth rate of the P population is, 104
where V MIN is the minimum growth (maximum kill) rates and MIC the corresponding minimum inhibitory 105 concentrations of the antibiotic. The parameter κ controls the shape of this function 17 . To account for the 106 resource limitation, we use the function R/(R+k) where k, the Monod constant, is the concentration of the 107 limiting resource where in the absence of the antibiotic the rate of is half its maximum value. The bacteria take 108 up resource at rates proportional to their maximum growth rates and a conversion efficiency parameter, e 109 (µg/cell). The population is maintained in continuous culture (chemostat-like) habitat into which resources 110 from a reservoir at a concentration of C µg/ml enter at a constant rate, w per hour, which is the same rate at 111 which excess resources, bacteria and antibiotics are removed. With these definitions and assumption, the rate 112 of change in the densities of the different populations of bacteria and concentration of antibiotics 113
where d is the rate of decay in the concentration of the antibiotic. 114
The simulation was programmed in Berkeley Madonna TM using Euler. 115
116 Galleria mellonella infection model 117 Twenty healthy 5th instar larvae each weighing 250 mg were injected with 2.5 x 10 6 CFU of S. aureus FPR3757 118 followed by 10 µg/ml LL-37 or 0.9 % NaCl for controls. One hour post infection, the larvae were treated with 15 119 mg/kg bodyweight of vancomycin, corresponding to a relevant clinical dose. The LL-37 pre-treatment and 120 antimicrobial therapy was repeated every 24 h for a total of 72 h and survival was monitored. Controls for 121 toxicity of LL-37 combined with the antimicrobials as well as for non-treated S. aureus infection were included 122 with all larvae receiving an equal number of injections of either active compound or 0.9 % NaCl. 
Results
130
Pre-exposure to LL-37 reduces S. aureus susceptibility to vancomycin 131
We have previously shown that pre-exposure of S. aureus to the antimicrobial peptide, colistin, reduces 132 vancomycin susceptibility 3 . To address if exposure to the human antimicrobial peptide LL-37 also affects 133 vancomycin susceptibility we initially measured the minimum inhibitory concentration (MIC) towards 134 vancomycin in the presence or absence of LL-37. While untreated S. aureus FPR3757 displayed vancomycin MIC 135 of 0.8 μg/ml, pre-treatment with LL-37 (MIC LL-37 = >128 μg/ml) for one hour at sub-inhibitory concentrations, 10 136 or 20 μg/ml, displayed vancomycin MIC of 1.2 and 1.4 μg/ml, respectively. To further examine the effect of LL-137 37 on vancomycin susceptibility, we spotted serial dilutions of cultures pre-treated with various sub-inhibitory 138 concentrations of LL-37 on agar plates containing increasing concentrations of vancomycin. Cultures exposed 139 to 40 μg/ml LL-37 were able to form colonies in the presence of 1.5 μg/ml vancomycin in contrast to untreated 140 cells, where no growth was observed (Figure 1) . 141
When observing the growth dynamics of treated and untreated cells in liquid cultures, pre-treatment with LL-142 37 notably reduced the vancomycin induced lag-phase measured as the time from inoculation until density 143 reached OD 600 = 0.1 (Figure 2a and b ). In the presence of vancomycin (at 0.75 μg/ml) the lag-phase was 24.5 144 (±1.9) h for untreated cells, whereas the lag-phase was 8.1 (±2.5) h following pre-exposure to 20 μg/ml LL-37 145 (p<0.001). Shortening of the lag phase was proportional to the concentration of LL-37 used for pre-treatment 146 (Figure 2a and b) . In the absence of vancomycin, LL-37 treatment did not affect growth kinetics (Figure 2a ). 147
When determining maximum growth rate, no effect of LL-37 was observed in the vancomycin-treated or 148 control cultures ( Figure S1 ), indicating that shortening of lag-phase rather than growth rate is important for the 149 LL-37 induced reduction in vancomycin susceptibility. 150
LL-37 induces reversible vancomycin tolerance 151
To examine if continuous LL-37 exposure is needed for the reduced vancomycin susceptibility we monitored 152 the LL-37 exposure time required before being able to observe reduced susceptibility to vancomycin and how 153 long the cells retained the reduced susceptibility after removal of LL-37. We found that the phenotype was 154 observed already after 10 minutes of exposure to LL-37 and that it lasted approximately 60 minutes after LL-37 155 was removed from the growth medium ( Figure 3) . These results demonstrate that the reduced vancomycin 156 susceptibility induced by LL-37 exposure is transient and non-inherited. 157
158
LL-37 reduces autolysis 159
Reduced susceptibility to vancomycin in genetically stable VISA strains are characterized phenotypically by a 160 decrease in Triton X-100 induced autolysis 9 . We examined the effect of LL-37 exposure (10 µg/ml) on autolysis 161 as described previously 3,7 . Compared to an un-treated control, the pre-treated culture showed less Triton X-100 162 induced autolysis (Figure 4) . concentration of antibiotic is significantly higher (≈5x) than the MIC, small increments in MIC do not markedly 172 affect the rate of clearance ( Figure 5 ). However, the lower the antibiotic concentration is at the site of 173 infection, the more impact the increased MIC will have on the rate of clearance. Maximum allowable 174 vancomycin concentration during treatment is limited by the nephrotoxic properties of the drug 19 and thus 175 clinical data 5 and our computer simulations indicate that the relatively small increase in MIC observed when S. 176 aureus is exposed to clinically relevant LL-37 concentrations may have a negative impact on the efficacy of 177 vancomycin in clearing an infection. 178
179
LL-37 abolishes antimicrobial effect of vancomycin in Galleria mellonella 180
The observed in vitro reduction in vancomycin susceptibility after LL-37 exposure combined with the 181 predictions of treatment failure associated with modest increments in MIC from our computer model 182 prompted us to test the efficacy of vancomycin in treating Galleria mellonella wax moth larvae 20 infected with 183 S. aureus FPR3757 in the presence or absence of LL-37. In the absence of LL-37, vancomycin reduced the 184 mortality inflicted by the MRSA strain. However, in the presence of LL-37, the antimicrobial potential of Vancomycin is one of the most important antibiotics for treatment of MRSA infections 26 . The CLSI susceptibility 200 breakpoint for vancomycin is 2 µg/ml 5 . Treatment failures reported for infections with MRSA strains being 201 susceptible to vancomycin has led to discussions whether the MIC breakpoint at 2 µg/ml should be further 202 decreased 5 . A meta-analysis associated high-MIC (≥ 1.5 µg/ml) MRSA isolates with increased risk of mortality 203 compared with low-MIC (< 1.5 µg/ml) MRSA isolates 5 , thus indicating that even minor increases in vancomycin 204 MIC can negatively affect treatment outcome and survival of patients with MRSA infections. 205
The impact of LL-37 on vancomycin susceptibility under in vivo conditions may vary from person to person. 206
Plasma levels of LL-37 in healthy individuals have been measured to be approximately 1 µg/ml, but with 207 variations between individuals from 0.5 to 3 µg/ml 27 . In areas of bacterial infection the local concentration will 208 reach even higher levels due to de-granulation of PMNs, e.g. in bronchoalveolar lavage fluid, where LL-37 209 concentrations from 5 to 25 µg/ml have been measured in infected individuals 28, 29 . Furthermore, LL-37 levels 210 are also influenced by disease conditions, where for example psoriasis patients have increased LL-37 levels 30 , 211 while atopic dermatitis patients have reduced levels 31 . Thus, it is conceivable that person-to-person variation in 212 LL-37 levels could influence susceptibility to vancomycin pointing to the importance of host factors in 213 antimicrobial chemotherapy. Survival of G. mellonella wax moth larvae infected with S. aureus FPR3757 and with or without LL-37 (10 µg/ml) 342 exposure followed by treatment with vancomycin (15 mg/kg bodyweight). Controls for non-treated S. aureus 343 infection and non-infected larvae exposed to combinations of the drugs were included. All larvae received 344 same number of injections. n=20 larvae for each condition. 345 Figure S1 . LL-37 effect on maximum growth rate.
368
From the growth experiments as described in Materials and Methods, the maximum growth rates were 369 determined for S. aureus cultures pre-exposed to LL-37 (0 to 20 µg/ml) for 1 h before being exposed to 
